Cerebral muscarinic acetylcholinergic receptor measurement in Alzheimer's disease patients on 11C-N-methyl-4-piperidyl benzilate - Comparison with cerebral blood flow and cerebral glucose metabolism

Annals of Nuclear Medicine

Volumn 12, Issue 1, 1998, Pages 35-42

  Yoshida, Tsuyoshi ^a   Kuwabara, Yasuo ^a   Ichiya, Yuichi ^a   Sasaki, Masayuki ^a   Fukumura, Toshimitsu ^a   Ichimiya, Atsushi ^b   Takita, Masashi ^b   Ogomori, Koji ^b   Masuda, Kouji ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

11C N methyl 4 piperidyl benzilate; Alzheimer's disease; Cerebral blood flow; Cerebral muscarinic acetylcholinergic receptor; Glucose metabolism

Indexed keywords

1 METHYL 4 PIPERIDYL BENZILATE; 1 METHYL 4 PIPERIDYL BENZILATE C 11; CHOLINERGIC RECEPTOR; FLUORODEOXYGLUCOSE F 18; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; MUSCARINIC RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN BLOOD FLOW; BRAIN METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GLUCOSE METABOLISM; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0031953757     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03165414     Document Type: Article

References (41)

1. Bartus RT, Dean RL III, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 217: 408-417, 1982.
2. Coyle JT, Price DL, Delong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 219: 1184-1190, 1983.
3. Mash DC, Flynn DD, Potter, LT. Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science 228: 1115-1117, 1985.
4. Holman BL, Gibson RE, Hill TC, Eckelman WC, Albert M, Reba RC. Muscarinic acetylcholine receptors in Alzheimer's disease. JAMA 254: 3063-3066, 1985.
5. Lee KS, Frey KA, Koeppe RA, Buck A, Mulholland GK, Foster NL, et al. Quantification of muscarinic cholinergic receptors in aging and Alzheimer's disease. J Nucl Med 32: 942-943, 1991. (Abstract)
6. 11C]NMPB), a muscarinic acetylcholine receptor antagonist. Nucl Med Biol 22: 13-17, 1995.
7. 11C]NMPB) in the rat. J Nucl Med 29: 768, 1988. (Abstract)
8. 11C]N-methyl-4-piperidyl benzilate binding to muscarinic cholinergic receptors. J Nucl Med 33: 882, 1992. (Abstract)
9. Zubieta JK, Frey KA, Koeppe RA, Kilbourn MR, Mulholland GK, Foster NL, et al. Muscarinic receptor binding in aging and Alzheimer's disease determined with [C-11]N-methyl-4-piperidyl benzilate and PET. J Nucl Med 35: 20, 1994. (Abstract)
10. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer's disease. Neurology 34: 939-944, 1987.
11. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, revised 3rd eds (DSM-III-R) American Psychiatric Association, Washington, 1987.
12. Folstein MF, Folstein SE, McHugh PR. "Mini Mental State." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198, 1975.
13. Hasegawa K, Inoue K, Moriya K. An investigation of dementia rating scale for the elderly. Seishinigaku 16: 965-969, 1974. (in Japanese)
14. Suhara T, Inoue O, Kobayashi K, Suzuki K, Tateno Y. Age-related changes in human muscarinic acetylcholine receptors measured by positron emission tomography. Neuroscience Letters 149: 225-228, 1993.
15. Bida GT, Satyamurthy N, Barrio JR. The synthesis of 2-[F-18]-fluoro-2-deoxy-D glucose using glycals: a reexamination. J Nucl Med 25: 1327-1334, 1984.
16. Chang LT. Group Research. A method for attenuation correction in radionuclide computed tomography. IEEE Transactions on Nuclear Science NS-25: 638-643, 1978.
17. 99mTc]-D,L-HMPAO in the human brain after intracarotid bolus injection: a kinetic analysis. J Cereb Blood Flow Metabol 8 (suppl 1): S13-S22, 1988.
18. 18F]2-fluoro-2-deoxy-D-glucose: Varidation of method. Ann Neural 6: 371-388, 1979.
19. Brooks RA. Alternative formula for glucose utilization using labeled deoxyglucose. J Nucl Med 23: 538-539, 1982.
20. Gjeddc A. Calculation of cerebral glucose phosphorylation from brain uptake of glucose analogs in vivo: a reexamina-tion. Brain Res Rev 4: 237-274, 1982.
21. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metabol 3: 1-7, 1983.
22. Wong DF, Wagner HN Jr, Dannals RF, Links JM, Frost JJ, Ravert HY, et al. Effects of age on dopamine and serotonin receptors measured by positron tomography in the living humam brain. Science 226: 1393-1396, 1984.
23. Dawson-Saunders B, Trapp RG. Basic and Clinical Biostatistics, 1st ed. Prentice Hall, 1990.
24. Rosner B. Fundamentals of Biostatistics, 4th ed. Duxbury Press, 1995.
25. Nordberg A. Neuroreceptor changes in Alzheimer disease. Cerehrovasc Brain Metab Rev 4: 303-328, 1992.
26. Weinberger DR, Jones DW, Reba RC, Mann U, Coppola R, Gibson R, et al. A comparison of FDG PET and IQNB SPECT in normal subjects and in patients with dementia. J Neuro-psychiatry Clinical Neurosci 4: 239-248, 1992.
27. Wyper DJ, Brown D, Patterson J, Owens J, Hunter R, Teasdale E, et al. Deficits in iodine-labeled 3-quinuclidinyl benzilate binding in relation to cerebral blood flow in patients with Alzheimer's disease. Eur J Nucl Med 20: 379-386, 1993.
28. Caulfield MP, Stragham DW, Cross AJ, Crow T, Birdsall NJ. Cortical muscarinic subtypes and Alzheimer's disease. Lancet ii: 1277, 1982.
29. 11C]tropanyl benzilate. J Cereb Blood Flow Metabol 16: 303-310, 1996.
30. Buck A, Mulholland GK. Papadopoulos SM, Koeppe RA, Frey KA. Kinetic evaluation of positron-emitting muscarinic receptor ligands employing direct intracarolid injection. J Cereb Blood Flow Metabol 16: 1280-1287, 1996.
31. Asahina M, Shinotoh H, Hirayama K, Suhara T, Shishido F, Inoue O, et al. Hypersensitivity of cortical muscarinic receptors in Parkinson's disease demonstrated by PET. Acta Neural Scand 91: 437-443, 1995.
32. Fukuyama H, Ogawa M, Yamauchi H, Yamaguchi S, Kimura J, Yonekura Y, et al. Altered cerebral energy metabolism in Alzheimer's disease. J Nucl Med 35: 1-6, 1994.
33. Korf J, Gramsbergen JB. Hippocampus pathology in dementia: postmortem assessed cation shifts and amino acid transmitter contents and its possible neuroimaging in vivo. Electroencephalogr Clin Neurophysiol 42 (suppl): 366-379, 1991.
34. Ohnishi T, Hoshi H, Nagamachi S, Jinnouchi S, Flores LG II, Futami S, et al. High-resolution SPECT to assess hippo-campal perfusion in neuropsychiatric diseases. J Nucl Med 36: 1163-1169, 1995.
35. Alavi A, Newberg AB, Souder E, Berlin JA. Quantitative analysis of PET and MRI data in normal aging and Alzheimer's disease: atrophy weighted total brain metabolism and absolute whole brain metabolism as reliable discriminators. J Nucl Med 34: 1681-1687, 1993.
36. Frackowiak RSJ, Pozzilli C, Legg NJ, Du Boulay GH, Marshall J, Lenzi GL, et al. Regional cerebral oxygen supply and utilization in dementia: a clinical and physiological study with oxygen-15 and positron tomography. Brain 104: 753-778, 1981.
37. Butler RW, Dickinson WA, Katholi C, Holsey JH. The comparative effect of organic brain disease on cerebral blood flow and measured intelligence. Ann Neural 13: 155-159, 1983.
38. O'Brien JT, Eagger S, Syed GMS, Sahakian BJ, Levy R. A study of regional cerebral blood flow and cognitive performance in Alzheimer's disease. J Neurol Neurosurg Psychiatry 55: 1182-1187, 1992.
39. Wong DF, Gjedde A, Wagner HN Jr. Quantification of neuroreceptors in the living human brain. I. Irreversible binding of ligands. J Cereb Blood Flow Metabol 6: 137-146, 1986.
40. 3H]pirenzepine. J Neurochem 46: 247-279, 1986.
41. 11C]tropanyl benzilate-binding to muscarinic cholinergic receptors: methodology and kinetic models alternatives. J Cereb Blood Flow Metabol 14: 85-99, 1994.